Research programme: antifungals - PfizerAlternative Names: Antifungals research programme - Pharmacia; VIC-107536
Latest Information Update: 14 Jan 2010
At a glance
- Originator Pharmacia Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 25 Jan 2005 Preclinical trials in Mycoses in USA (unspecified route)
- 18 Aug 2000 Preclinical development for Mycoses in USA (Unknown route)